CN Mobile Logo


Thyroid Cancer

Thyroid Cancer

Results of a phase II study indicated that the BRAF inhibitor vemurafenib was active in patients with BRAF V600E–mutated papillary thyroid cancer who were refractory to radioactive iodine.

Radioguided sentinel lymph node biopsy detected occult cervical lymph node metastases in about one-half of patients with thyroid nodules suspicious for papillary thyroid carcinoma, altering the management of their disease.

The multi-target RTK inhibitor anlotinib yielded a high response rate and was well tolerated in patients with advanced medullary thyroid carcinoma.

The addition of lenalidomide to cediranib failed to improve progression-free survival outcomes in patients with iodine 131–refractory differentiated thyroid cancer.

This management guide of endocrine malignancies covers the risk factors, diagnosis, screening, and treatment of both thyroid and parathyroid cancers.

Selumetinib has received Orphan Drug Designation status by the US Food and Drug Administration to be used as an adjuvant treatment in patients with stage III or IV differentiated thyroid cancer.

A new study is calling for a change in name for certain thyroid tumors. Patients diagnosed with what is currently known as noninvasive encapsulated follicular variant of papillary thyroid carcinoma have a very low risk for recurrence and therefore, researchers have suggested renaming the condition.


Subscribe to Thyroid Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.